专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060204577A1 Pharmaceutical Compositions of Drugs and Neutralized Acidic Polymers 有权
标题翻译：药物和中和酸性聚合物的药物组合物
公开(公告)号：US20060204577A1
公开(公告)日：2006-09-14
申请号：US11422133
申请日：2006-06-05
申请人： Marshall Crew , Dwayne Friesen , Rodney Ketner , Ravi Shanker , James West
发明人： Marshall Crew , Dwayne Friesen , Rodney Ketner , Ravi Shanker , James West
IPC分类号： A61K31/717 , A61K31/7024 , A61K31/498 , A61K31/4439 , A61K31/4745 , A61K9/24
CPC分类号： A61K9/1611 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/1652 , A61K31/00 , A61K31/404 , A61K31/405 , A61K31/4439 , A61K31/4706 , A61K31/4745 , A61K31/496 , A61K31/498 , A61K31/7024 , A61K31/717 , A61K2300/00
摘要： Pharmaceutical compositions comprised of low-solubility and/or acid-sensitive drugs and neutralized acidic polymers are disclosed.
摘要翻译：公开了由低溶解度和/或酸敏感性药物和中和的酸性聚合物组成的药物组合物。

2. 发明申请

US20060003011A1 Pharmaceutical compositions of drugs and neutralized acidic polymers 有权
公开(公告)号：US20060003011A1
公开(公告)日：2006-01-05
申请号：US11213118
申请日：2005-08-26
申请人： Marshall Crew , Dwayne Friesen , Rodney Ketner , Ravi Shanker , James West
发明人： Marshall Crew , Dwayne Friesen , Rodney Ketner , Ravi Shanker , James West
IPC分类号： A61K31/716 , A61K9/00 , A61K9/14
CPC分类号： A61K9/1611 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/1652 , A61K31/00 , A61K31/404 , A61K31/405 , A61K31/4439 , A61K31/4706 , A61K31/4745 , A61K31/496 , A61K31/498 , A61K31/7024 , A61K31/717 , A61K2300/00
摘要： Pharmaceutical compositions comprised of low-solubility and/or acid-sensitive drugs and neutralized acidic polymers are disclosed.

3. 发明申请

US20060216351A1 Pharmaceutical Compositions of Dispersions of Drugs and Neutral Polymers 审中-公开
标题翻译：药物和中性聚合物分散剂的药物组合物
公开(公告)号：US20060216351A1
公开(公告)日：2006-09-28
申请号：US11383520
申请日：2006-05-16
申请人： Dwayne Friesen , Michael Gumkowski , Rodney Ketner , Douglas Lorenz , James Nightingale , Ravi Shanker , James West
发明人： Dwayne Friesen , Michael Gumkowski , Rodney Ketner , Douglas Lorenz , James Nightingale , Ravi Shanker , James West
IPC分类号： A61K9/14
CPC分类号： A61K9/1652 , A61K9/10 , A61K9/146 , A61K9/1617 , A61K9/1635 , A61K9/1682 , A61K31/4965
摘要： In one aspect, pharmaceutical compositions comprising dispersions of an acid-sensitive drug and a neutral dispersion polymer are disclosed. The acid-sensitive drug has improved chemical stability relative to dispersions of the drug and acidic polymers. In another aspect, pharmaceutical compositions of low-solubility drugs and amphiphilic, hydroxy-functional vinyl copolymers are disclosed.
摘要翻译：一方面，公开了包含酸敏感药物和中性分散体聚合物分散体的药物组合物。酸敏感药物相对于药物和酸性聚合物的分散体具有改善的化学稳定性。另一方面，公开了低溶解度药物和两亲性羟基官能乙烯基共聚物的药物组合物。

4. 发明申请

US20050129772A1 Compositions comprising an HIV protease inhibitor 审中-公开
标题翻译：包含HIV蛋白酶抑制剂的组合物
公开(公告)号：US20050129772A1
公开(公告)日：2005-06-16
申请号：US11008325
申请日：2004-12-08
申请人： Scott Smith , Dwayne Friesen , Douglas Lorenz , David Lyon , Rodney Ketner , James West
发明人： Scott Smith , Dwayne Friesen , Douglas Lorenz , David Lyon , Rodney Ketner , James West
IPC分类号： A61K31/425 , C07D277/06 , A61K31/426 , A61K9/14 , C07D277/18
CPC分类号： C07D277/06
摘要： The present invention relates to pharmaceutical compositions comprising amorphous (4R)—N-allyl-3-{(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, their methods of preparation, their use in inhibiting the HIV protease enzyme, and their use in treating HIV-infected mammals, such as humans.
摘要翻译：本发明涉及包含无定形（4R）-N-烯丙基-3 - {（2S，3S）-2-羟基-3 - [（3-羟基-2-甲基苯甲酰基）氨基] -4-苯基丁酰基} - 5,5-二甲基-1,3-噻唑烷-4-甲酰胺或其药学上可接受的盐或溶剂合物，其制备方法，其用于抑制HIV蛋白酶的用途及其在治疗HIV感染的哺乳动物中的用途，作为人类

5. 发明申请

US20060029677A1 Azithromycin dosage forms with reduced side effects 审中-公开
公开(公告)号：US20060029677A1
公开(公告)日：2006-02-09
申请号：US11212433
申请日：2005-08-25
申请人： Timothy Hagen , Julian Lo , Avinash Thombre , Scott Herbig , Leah Appel , Marshall Crew , Dwayne Friesen , David Lyon , Scott McCray , James West
发明人： Timothy Hagen , Julian Lo , Avinash Thombre , Scott Herbig , Leah Appel , Marshall Crew , Dwayne Friesen , David Lyon , Scott McCray , James West
IPC分类号： A61K31/7052 , A61K9/14
CPC分类号： A61K9/1611 , A61K9/143 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1694 , A61K9/2009 , A61K9/2013 , A61K9/2031 , A61K31/7052
摘要： The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.

6. 发明申请

US20050181062A1 Multiparticulate crystalline drug compositions having controlled release profiles 有权
标题翻译：具有控制释放特性的多片晶体药物组合物
公开(公告)号：US20050181062A1
公开(公告)日：2005-08-18
申请号：US11004168
申请日：2004-12-03
申请人： Leah Appel , Roderick Ray , David Lyon , James West , Scott McCray , Marshall Crew , Dwayne Friesen , Scott Herbig , Julian Lo
发明人： Leah Appel , Roderick Ray , David Lyon , James West , Scott McCray , Marshall Crew , Dwayne Friesen , Scott Herbig , Julian Lo
IPC分类号： A61K9/16 , A61K31/00 , A61K31/4422 , A61K31/7032 , B29B9/00 , A61K31/455 , A61K31/496 , A61K31/7052
CPC分类号： A61K31/7032 , A61K9/1617 , A61K9/1635 , A61K9/1641 , A61K9/1694 , A61K31/4422
摘要： A multiparticulate for controlled release of a drug comprises crystalline drug, a glyceride having at least one alkylate substituent of at least 16 carbon atoms, and a poloxamer, wherein at least 70 wt % of the drug in the multiparticulate is crystalline.
摘要翻译：用于药物的控制释放的多颗粒包括结晶药物，具有至少一个至少16个碳原子的烷基化物取代基的甘油酯和泊洛沙姆，其中至少70重量％的多颗粒中的药物是结晶的。

7. 发明申请

US20050152982A1 Controlled release multiparticulates formed with dissolution enhancers 审中-公开
标题翻译：用溶解增强剂形成的控制释放多颗粒
公开(公告)号：US20050152982A1
公开(公告)日：2005-07-14
申请号：US11003853
申请日：2004-12-03
申请人： Leah Appel , Roderick Ray , David Newbold , David Lyon , James West , Dwayne Friesen , Scott McCray , Marshall Crew , Julian Lo
发明人： Leah Appel , Roderick Ray , David Newbold , David Lyon , James West , Dwayne Friesen , Scott McCray , Marshall Crew , Julian Lo
IPC分类号： A61K9/14 , A61K9/16 , A61K9/22 , A61K31/7052
CPC分类号： A61K9/1617
摘要： Pharmaceutical compositions of crystalline azithromycin-containing multiparticulates having low concentrations of azithromycin ester degradants and exhibiting controlled release of the drug are achieved by inclusion of dissolution enhancers having low concentrations of acid and ester substituents.
摘要翻译：通过包含具有低浓度的酸和酯取代基的溶解增强剂来实现具有低浓度的阿奇霉素酯降解物并显示药物释放控制的含结晶阿奇霉素的多颗粒的药物组合物。

8. 发明申请

US20050123627A1 Azithromycin dosage forms with reduced side effects 有权
标题翻译：阿奇霉素剂型具有减少的副作用
公开(公告)号：US20050123627A1
公开(公告)日：2005-06-09
申请号：US10763340
申请日：2004-01-23
申请人： Timothy Hagen , Julian Lo , Avinash Thombre , Scott Herbig , Leah Appel , Marshall Crew , Dwayne Friesen , David Lyon , Scott McCray , James West
发明人： Timothy Hagen , Julian Lo , Avinash Thombre , Scott Herbig , Leah Appel , Marshall Crew , Dwayne Friesen , David Lyon , Scott McCray , James West
IPC分类号： C07H17/00 , A61K9/00 , A61K9/16 , A61K9/20 , A61K31/7052 , A61K47/02 , A61K47/14 , A61K47/18 , A61K47/44 , A61P31/04 , A01N59/26 , A61K31/198 , A61K31/7008 , A61K33/10 , A61K33/42
CPC分类号： A61K9/1611 , A61K9/143 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1694 , A61K9/2009 , A61K9/2013 , A61K9/2031 , A61K31/7052
摘要： An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule. Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent. Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent. Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.
摘要翻译：包含阿奇霉素和有效量的碱化剂的口服剂型。优选地，所述口服剂型包含有效量的碱化剂和阿奇霉素多颗粒，其中所述多颗粒包括阿奇霉素，单山嵛酸甘油酯，二苯乙酸甘油酯和枸橼酸甘油酯和泊洛沙姆的混合物。通常，口服剂型包括任何合适的口服给药方式，例如用于口服悬浮液的粉末，单位剂量包或小药囊，片剂或胶囊。另外公开了包含阿奇霉素，有效量的碱化剂和载体的口服悬浮液。优选地，阿奇霉素是多颗粒形式，其中所述多颗粒包括阿奇霉素，甘油单山嵛酸甘油酯，二苯甲酸甘油酯和枸橼酸甘油酯和泊洛沙姆的混合物。还公开了一种减少与向哺乳动物施用阿奇霉素相关的胃肠道副作用的方法，包括向所述哺乳动物连续施用阿奇霉素和有效量的碱化剂，其中胃肠道副作用的频率低于施用相等剂量的阿奇霉素不含碱化剂。进一步公开的是一种在有需要的哺乳动物中治疗细菌或原生动物感染的方法，其包括向所述哺乳动物连续施用单剂量的口服剂型，其中所述口服剂型包含阿奇霉素和有效量的碱化剂。另外公开了包含阿奇霉素，表面活性剂的阿奇霉素多颗粒; 和药学上可接受的载体。

9. 发明申请

US20080015343A1 AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS 审中-公开
标题翻译： AZITHROMYCIN剂型减少副作用
公开(公告)号：US20080015343A1
公开(公告)日：2008-01-17
申请号：US11779489
申请日：2007-07-18
申请人： Timothy Hagen , Julian Lo , Avinash Thombre , Scott Herbig , Leah Appel , Marshall Crew , Dwayne Friesen , David Lyon , Scott McCray , James West
发明人： Timothy Hagen , Julian Lo , Avinash Thombre , Scott Herbig , Leah Appel , Marshall Crew , Dwayne Friesen , David Lyon , Scott McCray , James West
IPC分类号： C07H17/08
CPC分类号： A61K9/1611 , A61K9/143 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1694 , A61K9/2009 , A61K9/2013 , A61K9/2031 , A61K31/7052
摘要： The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.
摘要翻译：本发明涉及包含有效量的碱化剂和阿奇霉素多颗粒的口服剂型，其中所述多颗粒包含阿奇霉素，其包含甘油单硬脂酸甘油酯，二苯乙酸甘油酯，枸橼酸甘油酯或其混合物和泊洛沙姆的甘油酯。通常，口服剂型包括任何合适的口服给药方式，例如用于口服悬浮液的粉末，单位剂量包或小药囊，片剂或胶囊。

10. 发明申请

US20050181061A1 Extrusion process for forming chemically stable drug multiparticulates 有权
标题翻译：用于形成化学稳定的药物多颗粒的挤出方法
公开(公告)号：US20050181061A1
公开(公告)日：2005-08-18
申请号：US11004165
申请日：2004-12-03
申请人： Roderick Ray , Leah Appel , David Newbold , Dwayne Friesen , Scott McCray , David Lyon , James West , Marshall Crew
发明人： Roderick Ray , Leah Appel , David Newbold , Dwayne Friesen , Scott McCray , David Lyon , James West , Marshall Crew
IPC分类号： A61K9/00 , A61K9/14 , A61K9/16 , A61K9/22 , A61K31/00
CPC分类号： A61K9/1664 , A61K9/0095 , A61K9/1617 , A61K9/1641 , A61K9/1694 , A61K31/00
摘要： Reduced levels of drug degradation in drug-containing multiparticulates are obtained by an extrusion/melt-congeal process.
摘要翻译：通过挤出/熔融凝结过程获得含药多颗粒药物降解水平降低。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式